Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Here are the researchers who will lead the four networks of HIV trials and what each network will focus on.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
Some experts want to hold out for a more optimal vaccine. Others believe accepting the best possible vaccine sooner than later is ideal.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
Dr. Anthony Fauci will be a keynote speaker at USCHA in October. In his session, federal leaders will talk about next steps to ending HIV.
We asked participants and presenters at the #AIDS2020Virtual what was compelling to them about the gathering. Here are their responses.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.